FDA to publish CRLs ‘promptly’ as drugs are rejected
Regulatory NewsJoanne S. Eglovitch
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesBiotechnologyHealth Authority meeting and communication strategyLeadershipNew Drug Application (NDA)PharmaceuticalsProduct developmentRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)